Online inquiry

IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12134MR)

This product GTTS-WQ12134MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD248 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_020404.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57124
UniProt ID Q9HCU0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12134MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ705MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA A-1230717
GTTS-WQ4051MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BI 655130
GTTS-WQ5065MR IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CaCP-29
GTTS-WQ7189MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ2537MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 477
GTTS-WQ4386MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-224818
GTTS-WQ15847MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ4857MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BT-062
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW